Jane Street
ARQT icon

Jane Street’s Arcutis Biotherapeutics ARQT Stock Holding History

Jane Street’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
49,586
-234,037
-83% -$5.45M ﹤0.01% 5986
2026
Q1 		$6.68M Buy
283,623
+62,197
+28% +$1.59M ﹤0.01% 3089
2025
Q4 		$6.43M Sell
221,426
-139,344
-39% -$3.57M ﹤0.01% 2880
2025
Q3 		$6.8M Buy
360,770
+233,648
+184% +$3.68M ﹤0.01% 2956
2025
Q2 		$1.78M Buy
127,122
+10,646
+9% +$149K ﹤0.01% 4601
2025
Q1 		$1.82M Buy
116,476
+11,035
+10% +$155K ﹤0.01% 4514
2024
Q4 		$1.47M Sell
105,441
-5,631
-5% -$61.7K ﹤0.01% 4677
2024
Q3 		$1.03M Sell
111,072
-39,033
-26% -$385K ﹤0.01% 5822
2024
Q2 		$1.4M Sell
150,105
-63,431
-30% -$574K ﹤0.01% 5130
2024
Q1 		$2.12M Buy
213,536
+52,935
+33% +$395K ﹤0.01% 4026
2023
Q4 		$519K Buy
160,601
+37,576
+31% +$102K ﹤0.01% 6698
2023
Q3 		$653K Sell
123,025
-29,802
-20% -$253K ﹤0.01% 5849
2023
Q2 		$1.46M Buy
152,827
+126,572
+482% +$1.4M ﹤0.01% 4634
2023
Q1 		$289K Buy
+26,255
New +$380K ﹤0.01% 7264
2022
Q4 		– Sell
-19,081
Closed -$365K – 9091
2022
Q3 		$365K Buy
+19,081
New +$432K ﹤0.01% 7246
2022
Q2 		– Sell
-14,398
Closed -$295K – 9602
2022
Q1 		$277K Buy
+14,398
New +$244K ﹤0.01% 8523
2020
Q4 		– Sell
-10,959
Closed -$321K – 7435
2020
Q3 		$321K Buy
+10,959
New +$293K ﹤0.01% 5786

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jane Street's ARQT Position: Q2 2026 in Review

Jane Street reduced its Arcutis Biotherapeutics (ARQT) stake by 83% in Q2 2026, selling an estimated $5.45M and leaving 49,586 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #5986.

Jane Street first reported a position in ARQT in Q3 2020 and has held it in 17 quarters since. The position peaked at $6.8M in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jane Street held 49,586 shares of Arcutis Biotherapeutics worth $1.3M as of Q2 2026.
  • Jane Street sold 234,037 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.45M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5986 holding.
  • Jane Street first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 17 quarters since.
  • Jane Street's Arcutis Biotherapeutics position peaked at $6.8M in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.